Form 4 Ginkgo Bioworks Holdings For: Sep 16 Filed by: Eagle Equity Partners III, LLC

September 22, 2021 9:57 PM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person *
Eagle Equity Partners III, LLC

(Last) (First) (Middle)
C/O GINKGO BIOWORKS HOLDINGS, INC.
27 DRYDOCK AVENUE

(Street)
BOSTON MA 02210

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Ginkgo Bioworks Holdings, Inc. [ DNA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) X Other (specify below)
*Director by Deputization
3. Date of Earliest Transaction (Month/Day/Year)
09/16/2021
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 09/16/2021   D (1)   11,534,052 D (1) 31,590,948 D  
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Class B Ordinary Shares (1) 09/16/2021   M (1)     43,125,000   (1)   (1) Class A Common Stock 43,125,000 (1) 0 D  
Private Placement Warrants $ 11.5 09/16/2021   A   19,250,000     (2)   (2) Class A Common Stock 19,250,000 $ 10 19,250,000 D  
Private Placement Warrants $ 11.5 09/16/2021   D (3)     1,925,000   (2)   (2) Class A Common Stock 1,925,000 (3) 17,325,000 D  
Explanation of Responses:
1. In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as Soaring Eagle Acquisition Corp. or "Soaring Eagle") and Ginkgo Bioworks, Inc. ("Ginkgo"), among other things, each share of Soaring Eagle's Class B ordinary shares converted pursuant to the terms of such shares into shares of the Issuer's Class A common stock on a one-for-one basis. Simultaneously, pursuant to the Sponsor Support Agreement, dated as of May 11, 2021 (the "Sponsor Support Agreement") between the Reporting Person, Ginkgo, Soaring Eagle and certain other shareholders, the Reporting Person forfeited to the Issuer at no cost 11,534,052 shares of the Issuer's Class A common stock, which was exempted pursuant to Rule 16b-3(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
2. The private placement warrants were acquired from the Issuer in connection with its initial public offering, the terms of which are described under the heading "Description of Securities" in the Issuer's registration statement on Form S-1 (File No. 333-251661). Each private placement warrant is exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share, subject to certain adjustments. The private placement warrants are reported as acquired for purposes of Section 16 of the Exchange Act concurrently with the Closing, because they did not become derivative securities until such date based on the terms of their exercisability.
3. Pursuant to the Sponsor Support Agreement, the Reporting Person forfeited to the Issuer at the Closing 10% of the private placement warrants it then held at no cost, which was exempted pursuant to Rule 16b-3(e) under the Exchange Act.
/s/ Eli Baker 09/22/2021
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings